

# Moazzam Shahzad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993502/publications.pdf>

Version: 2024-02-01

57  
papers

153  
citations

1874746  
5  
h-index

1427216  
11  
g-index

57  
all docs

57  
docs citations

57  
times ranked

102  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. <i>Transplant Immunology</i> , 2022, 70, 101520.  | 0.6 | 6         |
| 2  | Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .   | 0.7 | 28        |
| 3  | Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1708-1713.   | 0.6 | 6         |
| 4  | Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S453-S454.   | 0.6 | 0         |
| 5  | Outcomes of Autologous Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S412-S413.                      | 0.6 | 0         |
| 6  | Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S119.    | 0.6 | 0         |
| 7  | Socioeconomic and Racial Barriers to CD19 Chimeric Antigen Receptor T Cell Therapy (CART) Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S208.  | 0.6 | 0         |
| 8  | Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S122. | 0.6 | 0         |
| 9  | Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S416-S417.        | 0.6 | 0         |
| 10 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S204.    | 0.6 | 0         |
| 11 | Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation: A Systemic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S262-S263. | 0.6 | 0         |
| 12 | Outcomes with Allogeneic Hematopoietic Stem Cell Transplant in Therapy-Related Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S114.      | 0.6 | 0         |
| 13 | Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 358-364.  | 0.6 | 40        |
| 14 | Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 2671-2678.                                   | 0.6 | 0         |
| 15 | Role of biogenetic markers in differentiation and prognosis of giant cell tumor: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23514-e23514.  | 0.8 | 0         |
| 16 | Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18611-e18611.            | 0.8 | 1         |
| 17 | Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19025-e19025.   | 0.8 | 0         |
| 18 | Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7033-7033.  | 0.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.. Journal of Clinical Oncology, 2021, 39, e19035-e19035.  | 0.8 | 0         |
| 20 | Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, e19014-e19014.                | 0.8 | 2         |
| 21 | Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, e19021-e19021.                                       | 0.8 | 1         |
| 22 | Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.. Journal of Clinical Oncology, 2021, 39, 11020-11020.   | 0.8 | 0         |
| 23 | Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.. Journal of Clinical Oncology, 2021, 39, e20014-e20014.   | 0.8 | 0         |
| 24 | Management of light chain deposition disease: A systematic review.. Journal of Clinical Oncology, 2021, 39, e20042-e20042.   | 0.8 | 0         |
| 25 | Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 659-666.  | 0.2 | 1         |
| 26 | Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplantation and Cellular Therapy, 2021, 27, 796.e1-796.e7.  | 0.6 | 42        |
| 27 | Advances in viral oncolytics for treatment of multiple myeloma – a focused review. Expert Review of Hematology, 2021, 14, 1071-1083.   | 1.0 | 3         |
| 28 | Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 877.e1-877.e8.  | 0.6 | 20        |
| 29 | S3297 – Effect of Gastrointestinal Hemorrhage in Patients Admitted With Gastrointestinal Lymphomas. American Journal of Gastroenterology, 2021, 116, S1359-S1359.  | 0.2 | 0         |
| 30 | Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review. Blood, 2021, 138, 4521-4521.   | 0.6 | 0         |
| 31 | Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3147-3147.   | 0.6 | 0         |
| 32 | Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4389-4389.  | 0.6 | 0         |
| 33 | Evolution in Resource Utilization for Unique Toxicities Related to Chimeric Antigen Receptor T Cell Therapy from 2017 to 2020: A Database Review. Blood, 2021, 138, 4844-4844.   | 0.6 | 0         |
| 34 | Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3961-3961. | 0.6 | 0         |
| 35 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4825-4825.   | 0.6 | 0         |
| 36 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4683-4683.  | 0.6 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3963-3963.   | 0.6 | 0         |
| 38 | Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting. Blood, 2021, 138, 2823-2823.  | 0.6 | 0         |
| 39 | Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Blood, 2021, 138, 4410-4410.                                    | 0.6 | 0         |
| 40 | Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1848-1848.   | 0.6 | 0         |
| 41 | Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4910-4910.   | 0.6 | 0         |
| 42 | Outcomes with Interferon in Polycythemia Vera: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3659-3659.   | 0.6 | 0         |
| 43 | Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1847-1847.  | 0.6 | 0         |
| 44 | Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2863-2863.                  | 0.6 | 0         |
| 45 | Impact of Natural Killer Cells Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4880-4880.                                    | 0.6 | 0         |
| 46 | Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Blood, 2021, 138, 4790-4790.   | 0.6 | 0         |
| 47 | Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4831-4831.                                 | 0.6 | 0         |
| 48 | Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4824-4824. | 0.6 | 0         |
| 49 | Bispecific T-Cell Engager Antibodies in Multiple Myeloma- a Systematic Review of Phase 1 Clinical Trials. Blood, 2021, 138, 4775-4775.   | 0.6 | 0         |
| 50 | Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 39-40.   | 0.6 | 2         |
| 51 | Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials. Blood, 2020, 136, 26-27.   | 0.6 | 0         |
| 52 | A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials. Blood, 2020, 136, 36-37.   | 0.6 | 1         |
| 53 | Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 4-5.  | 0.6 | 0         |
| 54 | A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 7-7.   | 0.6 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 32-33.   | 0.6 | 0         |
| 56 | Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review. Blood, 2020, 136, 29-30. | 0.6 | 0         |
| 57 | Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Eligible Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 36-36.                     | 0.6 | 0         |